NCT07096908View on ClinicalTrials.gov

Tirzepatide Use in People With Obesity and Type 1 Diabetes

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

February 25, 2028

Study Completion Date

August 1, 2028

Conditions
Type1diabetesObesity
Interventions
DRUG

Tirzepatide

weekly injections

DRUG

Placebo

weekly injections

Trial Locations (1)

15462

Dasman Diabetes Institute, Kuwait City

All Listed Sponsors
collaborator

University of Ulster

OTHER

lead

Dasman Diabetes Institute

OTHER